24:56

Cybin’s Phase 3 Launch & 12-Month CYB003 Data – Interview with CEO Doug Drysdale (NYSE:CYBN)

17:58

Compass Pathways' Updates | First and Second Movers | MindMed and Cybin Approaching Phase 3

07:03

DMT Trip Report: Infinite Fractals of Pure Joy

53:18

Generating the Data | MindMed Prepares for Pivotal Trials | (NASDAQ:MNMD)

37:51

Psychedelic Drug Development: What We Are Looking Out For

46:00

Generating the Data | atai Life Sciences’ Focus on Interventional Psychiatry | (NASDAQ:ATAI)

38:00

The Potential of Psilera's Next Generation Neuroplastogens: An Interview with Dr. Chris Witowski

22:39

Generating the Data: Cybin Prepares for Phase 3 | $CYBN

20:39

Why We Are Not Worried About Psychedelic Medicine Moving Forward

55:27

Psychedelics and Addiction Recovery: An Interview with Dr. Rick Barnett

01:26:02

The DMT Episode - Extended State DMT | N,N-DMT | 5-MeO-DMT | Ayahuasca | with Guest Dr. Del Potter

25:45

Wake-Up Call | MAPS/Lykos Therapeutics | MDMA-AT

55:49

Terran Biosciences' Transformative Therapeutics | An Interview with Founder and CEO, Dr. Sam Clark

01:02:10

Healing Veterans with Psychedelics | An Interview with Matthew ("Whiz") Buckley | No Fallen Heroes

23:27

Skipping the Trip | Abbvie x Gilgamesh Pharmaceuticals: The Epic of Gilgamesh Continued

05:48

Psilocybin Trip Report: Life-Changing Mushroom Experience

01:00:57

Investing Across the Psychedelic Medicine Ecosystem: An Interview with Cody Shandraw

11:43

DMT Trip Report: The Green Woman

43:54

The Big Picture with Psychedelic Medicine: An Interview with Christian Angermayer

03:34

5-MeO-DMT Trip Report: Letting Go

15:03

Psychedelic Biotech Stock Portfolio Updates

03:26

Psilocybin Trip Report: It's Okay to Cry

25:28

Cybin’s Psilocybin Breakthrough | An Interview with CEO Doug Drysdale | $CYBN

14:13

Mindmed $MNMD | LSD’s Future in Psychiatry

03:01

DMT Trip Report: Am I Dead?

02:54

$MNMD MindMed's Impressive 12-Week Data and Breakthrough Therapy Designation for LSD

02:27

DMT Trip Report: Overcoming Heartbreak

31:51

PSYLO's Next Generation Psychedelic Pipeline: An Interview with CSO and Co-Founder Sam Banister

02:13

DMT Trip Report: I Broke Through..

09:08

What's Going on with Cybin $CYBN?

44:35

Ibogaine's Future in Neuropsychiatry: Treating Addiction and Healing Brain Trauma | Dr. Deborah Mash

28:40

Power Moves | atai Life Sciences x Beckley Psytech | $ATAI

32:40

Analyzing the Psychedelic Biotech Sector with The Chart Guys | $ATAI , $MNMD , $CYBN , $GHRS , $CMPS

12:15

Groundbreaking Results from Mindmed $MNMD and Cybin $CYBN | Psychedelic Vantage

15:56

The Future Role of Psychedelics in Addiction Recovery | Psychedelic Vantage

15:21

Jake's Current Psychedelic Medicine Stock Portfolio | Psychedelic Vantage

21:43

Comprehensive Analysis of Compass Pathways: $CMPS | Psychedelic Vantage

17:29

Doug Drysdale, CEO of Cybin, Breaks Down Cybin’s Phase 1/2a Interim Data Using Intramuscular N,N-DMT

22:53

Long vs. Short vs. Non-Hallucinogenic Psychedelics | Psychedelic Vantage Podcast

26:35

DMT and Depression: A Conversation with Neuroscientist Dr. Elemer Piros - Part 2

25:50

DMT and Depression: A Conversation with Neuroscientist Dr. Elemer Piros - Part 1

22:14

($CYBN) Cybin: All Hype or the Real Deal? | Psychedelic Vantage

31:29

Revolutionizing Addiction Recovery: CEO Anthony Tennyson of Awaken Life Sciences $AWKNF

51:41

Altered States: CEO Dillan DiNardo of Mindstate Design Labs

08:06

Mindmed ($MNMD): Upcoming Catalysts | Psychedelic Vantage

09:08

Cybin $CYBN: Talking Small Pharma Acquisition with CEO Doug Drysdale | Psychedelic Vantage

01:14:10

Empath Ventures: Funding the Future of Psychedelic Medicine | Psychedelic Vantage

54:46

Nushama Wellness Founders on the Science and Soul of Ketamine Therapy | Psychedelic Vantage

48:05

Interview with CEO Florian Brand and CSO Dr. Srinivas Rao of atai Life Sciences | $ATAI

34:14

Breaking Barriers in Ketamine Therapy: Interview with Jonathan Sabbagh, CEO of Journey Clinical

01:15:29

Exploring the Psychedelic Biotech Sector: Interview with Elemer Piros, Senior Biotechnology Analyst

15:56

The Spirit Molecule: Looking at NN-DMT in Psychedelic Biotech | Psychedelic Insights

01:09:29

Del Potter: Exploring DMT, Ayahuasca, and his Journey Working with Alexander Shulgin

37:19

Navigating the Psychedelic Renaissance: A Conversation with Cybin's CEO, Doug Drysdale

19:24

Unveiling the Epic of Gilgamesh: A Deep Dive into Gilgamesh Pharmaceuticals' Pipeline

54:14

Unlocking the Mind: Exclusive Interview with CEO Ian McDonald | Bright Minds Biosciences $DRUG

20:20

ATAI Life Sciences: Earnings Report Breakdown and Pipeline Highlights | $ATAI

29:38

Exploring GH Research ($GHRS): The Compass Pathways of 5-MeO-DMT

39:55

The Future of Psychedelic Medicine: An Interview with Mindset Pharma ($MSSTF) CEO James Lanthier

11:04

ATAI x Small Pharma | Field Trip's Fight Against Bankruptcy